Ipsen Biopharmaceuticals, Inc.
IPSEYDrugs in Pipeline
62
Phase 3 Programs
41
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 3 past
BLI800
Diagnosis Disease
Lanreotide Autogel®
Acromegaly
Lanreotide (Autogel formulation)
Acromegaly
Odevixibat
Biliary Atresia
Corabotase
Moderate to Severe Glabellar Lines
Somatuline Autogel (lanreotide acetate)
Acromegaly
IPN10200
Moderate to Severe Upper Facial Lines
Triptorelin Pamoate 11.25mg
Prostate Cancer
lanreotide (Autogel formulation), duration of treatment 46-48 weeks
Acromegaly
Irinotecan liposome injection
Small Cell Lung Cancer
Triptorelin (Decapeptyl®)
Prostate Cancer
Palovarotene
Fibrodysplasia Ossificans Progressiva (FOP)
Smecta (Diosmectite), duration of treatment - 7 days
Diarrhoea
Triptorelin Pamoate
Central Precocious Puberty
Lanreotide Autogel
Intestinal Obstruction
EGb 761® (Tanakan®)
Multiple Sclerosis, Relapsing-Remitting
PEG 4000 (Forlax®)
Chronic Constipation
Triptorelin embonate 22.5 mg
Prostate Cancer
Triptorelin Pamoate PR 3-month
Endometriosis
A4250 (odevixibat)
Progressive Familial Intrahepatic Cholestasis
Pegvisomant
Acromegaly
Elafibranor 80mg
Primary Biliary Cirrhosis
rhIGF-1 (mecasermin, Tercica, Inc.)
Growth Disorders
Irinotecan Liposomal Injection
Metastatic Adenocarcinoma of the Pancreas
Eziclen®/Izinova®
Digestive System Disease
Triptorelin pamoate (embonate) salt
Advanced Prostate Cancer
Elafibranor
Primary Biliary Cholangitis
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
Acromegaly
Triptorelin pamoate 11.25mg (Decapeptyl® SR)
Precocious Puberty
Botulinum toxin type A
Glabellar Frown Lines
Triptorelin (I.N.N.)
Precocious Puberty
EGb761
Stroke, Acute
mecasermin
Growth Hormone Insensitivity Syndrome
Eziclen
Bowel Cleansing
rhIGF-1 (mecasermin) for a period of 86 weeks
Insulin-Like Growth Factor-1 Deficiency
Lanreotide
Carcinoid Syndrome
Triptorelin pamoate 15mg
Central Precocious Puberty
Lanreotide microparticles
Digestive Fistulae
Somatropin (rDNA origin)
Turner Syndrome
Lanreotide autogel 120 mg
Acromegaly
Lanreotide (microparticle formulation)
Intestinal Obstruction
Lanreotide PRF
Acromegaly
IPN01195
Advanced Solid Tumor
nal-IRI
Pancreatic Cancer
IPN60300
Locally Advanced Solid Tumor
IPN01203
Advanced Solid Tumor
Elafibranor 80 mg
Primary Sclerosing Cholangitis
IPN01194
Melanoma
Triptorelin Pamoate (Pamorelin® LA 11.25 mg)
Prostate Cancer
BN83495
Endometrial Cancer
satoreotide trizoxetan
Gastroenteropancreatic Neuroendocrine Tumors
Dysport
Spasticity
Cabozantinib 40 MG
Esophageal Cancer
Temozolomide (TMZ)
Gastroenteropancreatic Neuroendocrine Tumors
Ritivixibat
Primary Sclerosing Cholangitis
Lanreotide (Autogel formulation) and Temozolomide
Neuroendocrine Tumours
Diflomotecan (BN80915)
Small Cell Lung Cancer
Tasquinimod
Advanced or Metastatic Hepatocellular Cancer
EGb 761 120 mg
Friedreich Ataxia
IPN10200 dose A
Episodic Migraine
EGb761®
Alzheimer's Disease
Satoreotide trizoxetan 5-20μg
Gastro-Enteropancreatic Neuroendocrine Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BLI800 | Phase 3 | Diagnosis Disease | - | - |
Lanreotide Autogel® | Phase 3 | Acromegaly | - | - |
Lanreotide (Autogel formulation) | Phase 3 | Acromegaly | - | - |
Odevixibat | Phase 3 | Biliary Atresia | - | - |
Corabotase | Phase 3 | Moderate to Severe Glabellar Lines | - | - |
Somatuline Autogel (lanreotide acetate) | Phase 3 | Acromegaly | - | - |
IPN10200 | Phase 3 | Moderate to Severe Upper Facial Lines | - | - |
Triptorelin Pamoate 11.25mg | Phase 3 | Prostate Cancer | - | - |
lanreotide (Autogel formulation), duration of treatment 46-48 weeks | Phase 3 | Acromegaly | - | - |
Irinotecan liposome injection | Phase 3 | Small Cell Lung Cancer | - | - |
Triptorelin (Decapeptyl®) | Phase 3 | Prostate Cancer | - | - |
Palovarotene | Phase 3 | Fibrodysplasia Ossificans Progressiva (FOP) | - | - |
Smecta (Diosmectite), duration of treatment - 7 days | Phase 3 | Diarrhoea | - | - |
Triptorelin Pamoate | Phase 3 | Central Precocious Puberty | - | - |
Lanreotide Autogel | Phase 3 | Intestinal Obstruction | - | - |
EGb 761® (Tanakan®) | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
PEG 4000 (Forlax®) | Phase 3 | Chronic Constipation | - | - |
Triptorelin embonate 22.5 mg | Phase 3 | Prostate Cancer | - | - |
Triptorelin Pamoate PR 3-month | Phase 3 | Endometriosis | - | - |
A4250 (odevixibat) | Phase 3 | Progressive Familial Intrahepatic Cholestasis | - | - |
Pegvisomant | Phase 3 | Acromegaly | - | - |
Elafibranor 80mg | Phase 3 | Primary Biliary Cirrhosis | - | - |
rhIGF-1 (mecasermin, Tercica, Inc.) | Phase 3 | Growth Disorders | - | - |
Irinotecan Liposomal Injection | Phase 3 | Metastatic Adenocarcinoma of the Pancreas | - | - |
Eziclen®/Izinova® | Phase 3 | Digestive System Disease | - | - |
Triptorelin pamoate (embonate) salt | Phase 3 | Advanced Prostate Cancer | - | - |
Elafibranor | Phase 3 | Primary Biliary Cholangitis | - | - |
lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval | Phase 3 | Acromegaly | - | - |
Triptorelin pamoate 11.25mg (Decapeptyl® SR) | Phase 3 | Precocious Puberty | - | - |
Botulinum toxin type A | Phase 3 | Glabellar Frown Lines | - | - |
Triptorelin (I.N.N.) | Phase 3 | Precocious Puberty | - | - |
EGb761 | Phase 3 | Stroke, Acute | - | - |
mecasermin | Phase 3 | Growth Hormone Insensitivity Syndrome | - | - |
Eziclen | Phase 3 | Bowel Cleansing | - | - |
rhIGF-1 (mecasermin) for a period of 86 weeks | Phase 3 | Insulin-Like Growth Factor-1 Deficiency | - | - |
Lanreotide | Phase 3 | Carcinoid Syndrome | - | - |
Triptorelin pamoate 15mg | Phase 3 | Central Precocious Puberty | - | - |
Lanreotide microparticles | Phase 3 | Digestive Fistulae | - | - |
Somatropin (rDNA origin) | Phase 3 | Turner Syndrome | - | - |
Lanreotide autogel 120 mg | Phase 3 | Acromegaly | - | - |
Lanreotide (microparticle formulation) | Phase 3 | Intestinal Obstruction | - | - |
Lanreotide PRF | Phase 2 | Acromegaly | - | - |
IPN01195 | Phase 2 | Advanced Solid Tumor | - | - |
nal-IRI | Phase 2 | Pancreatic Cancer | - | - |
IPN60300 | Phase 2 | Locally Advanced Solid Tumor | - | - |
IPN01203 | Phase 2 | Advanced Solid Tumor | - | - |
Elafibranor 80 mg | Phase 2 | Primary Sclerosing Cholangitis | - | - |
IPN01194 | Phase 2 | Melanoma | - | - |
Triptorelin Pamoate (Pamorelin® LA 11.25 mg) | Phase 2 | Prostate Cancer | - | - |
BN83495 | Phase 2 | Endometrial Cancer | - | - |
satoreotide trizoxetan | Phase 2 | Gastroenteropancreatic Neuroendocrine Tumors | - | - |
Dysport | Phase 2 | Spasticity | - | - |
Cabozantinib 40 MG | Phase 2 | Esophageal Cancer | - | - |
Temozolomide (TMZ) | Phase 2 | Gastroenteropancreatic Neuroendocrine Tumors | - | - |
Ritivixibat | Phase 2 | Primary Sclerosing Cholangitis | - | - |
Lanreotide (Autogel formulation) and Temozolomide | Phase 2 | Neuroendocrine Tumours | - | - |
Diflomotecan (BN80915) | Phase 2 | Small Cell Lung Cancer | - | - |
Tasquinimod | Phase 2 | Advanced or Metastatic Hepatocellular Cancer | - | - |
EGb 761 120 mg | Phase 2 | Friedreich Ataxia | - | - |
IPN10200 dose A | Phase 2 | Episodic Migraine | - | - |
EGb761® | Phase 2 | Alzheimer's Disease | - | - |
Satoreotide trizoxetan 5-20μg | Phase 2 | Gastro-Enteropancreatic Neuroendocrine Tumor | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Ipsen Biopharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 62 drug candidates in Ipsen Biopharmaceuticals, Inc.'s (IPSEY) pipeline across Phase 3, Phase 2. Its lead program is BLI800 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Ipsen Biopharmaceuticals, Inc.'s next FDA catalyst?→
Ipsen Biopharmaceuticals, Inc.'s (IPSEY) next tracked catalyst is a Phase 3 expected August 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IPSEY biotech catalysts?→
Add IPSEY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Ipsen Biopharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.